AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF

NCT00396266 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Lymphoma, Non-Hodgkin

Interventions

DRUG: G-CSF Plus Plerixafor

Sponsor

Genzyme, a Sanofi Company